STOCK MARKET BSE NSE

DRDO to get 2 per cent royalty from Dr Reddy's on sale of anti-Covid drug 2-DG in India: Government

The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May.

Published: 28th July 2021 07:41 PM  |   Last Updated: 28th July 2021 07:41 PM   |  A+A-

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan release first batch of Anti-COVID drug 2DG developed by DRDO

Defence Minister Rajnath Singh and Union Health Minister Dr Harsh Vardhan releasing the first batch of Anti-COVID drug 2DG developed by DRDO on 17 May, 2021. (File photo | ANI)

By PTI

NEW DELHI: The Defence Research and Development Organisation (DRDO) will get two per cent royalty from Dr Reddy's Laboratory (DRL) on the sale of anti-COVID drug 2-DG, Minister of State for Defence Ajay Bhatt said on Wednesday.

In a written reply to a question in the Lok Sabha, Bhatt said the DRDO developed the technology (for 2-DG) along with DRL, Hyderabad.

The pricing is solely decided by DRL.

The actual price fixed by Dr Reddy lab is Rs 990 per sachet, he said.

The DRDO works under the Defence Ministry.

DRL is a private listed company.

"DRDO will get 2 per cent royalty on the sale of 2-DG in the Indian market as per Transfer of Technology agreement," Bhatt said.

The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May.

The first batch of this oral drug, developed by the DRDO was released on May 17 by Defence Minister Rajnath Singh and then Health Minister Harsh Vardhan.

The Defence Ministry on May 8 had said that the clinical trials of 2-DG showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

The drug comes in powder form in sachet and is taken orally by dissolving it in water.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp